Celularity (CELU) Non Operating Income (2019 - 2025)
Celularity (CELU) posted quarterly Non Operating Income of -$2.3 million for Q4 2025, up 83.53% year-over-year from -$1.3 million in Q4 2024, and down 199.22% quarter-over-quarter from -$769000.0 in Q3 2025.
Celularity (CELU) Non Operating Income (2019 - 2025) Analysis & Trends
Celularity (CELU) has reported Non Operating Income for 7 consecutive years, with -$2.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non Operating Income rose 83.53% year-over-year to -$2.3 million; the TTM figure through Dec 2025 stood at -$13.1 million (up 60.54% YoY), while the FY2025 annual figure was -$30.4 million, down 55.65% from the prior year.
- Non Operating Income fell to -$2.3 million in Q4 2025 per CELU's latest filing, from -$769000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $43.7 million in Q2 2022 and bottomed at -$21.3 million in Q1 2022.
- Historically, Non Operating Income has averaged $1.4 million across 5 years, with a median of -$1.6 million in 2024.
- On a YoY basis, Non Operating Income climbed as much as 2279.04% in 2022 and fell as far as 78614.81% in 2022.
- Celularity's Non Operating Income stood at $10.9 million in 2021, then tumbled by 36.31% to $7.0 million in 2022, then sank by 153.98% to -$3.8 million in 2023, then slumped by 271.71% to -$14.0 million in 2024, then soared by 83.53% to -$2.3 million in 2025.
- Business Quant data shows CELU's Non Operating Income at -$2.3 million in Q4 2025, -$769000.0 in Q3 2025, and -$8.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn | -2.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.30 Mn |
| Sep 30, 2025 | -769,000.00 |
| Jun 30, 2025 | -8.66 Mn |
| Mar 31, 2025 | -1.40 Mn |
| Dec 31, 2024 | -13.97 Mn |
| Sep 30, 2024 | -2.90 Mn |
| Jun 30, 2024 | -1.77 Mn |
| Mar 31, 2024 | -14.64 Mn |
| Dec 31, 2023 | -3.76 Mn |
| Sep 30, 2023 | 5.38 Mn |
| Jun 30, 2023 | -5.47 Mn |
| Mar 31, 2023 | -147,000.00 |
| Dec 31, 2022 | 6.96 Mn |
| Sep 30, 2022 | 1.28 Mn |
| Jun 30, 2022 | 43.67 Mn |
| Mar 31, 2022 | -21.25 Mn |
| Dec 31, 2021 | 10.93 Mn |
| Sep 30, 2021 | 39.04 Mn |
| Jun 30, 2021 | -2.00 Mn |
| Mar 31, 2021 | -27,000.00 |